S.Biomedics Co. Ltd.
S.Biomedics CO., LTD., a biopharmaceutical company, engages in the research and development of stem cells therapy products. Its product pipeline comprises TED-N, which is in phase 1/2a clinical development for the treatment of subacute spinal cord injury; TED-A9, which is in phase 1/2a clinical development for the treatment of parkinson's disease; FECS-Ad, which is 1/2a for the treatment of criti… Read more
S.Biomedics Co. Ltd. (304360) - Net Assets
Latest net assets as of March 2025: ₩10.46 Billion KRW
Based on the latest financial reports, S.Biomedics Co. Ltd. (304360) has net assets worth ₩10.46 Billion KRW as of March 2025.
Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets (₩44.36 Billion) and total liabilities (₩33.89 Billion). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | ₩10.46 Billion |
| % of Total Assets | 23.59% |
| Annual Growth Rate | N/A |
| 5-Year Change | N/A |
| 10-Year Change | N/A |
| Growth Volatility | N/A |
S.Biomedics Co. Ltd. - Net Assets Trend (2022–2024)
This chart illustrates how S.Biomedics Co. Ltd.'s net assets have evolved over time, based on quarterly financial data. Explore and compare other companies by net assets.
Annual Net Assets for S.Biomedics Co. Ltd. (2022–2024)
The table below shows the annual net assets of S.Biomedics Co. Ltd. from 2022 to 2024.
| Year | Net Assets | Change |
|---|---|---|
| 2024-12-31 | ₩11.86 Billion | +71.16% |
| 2023-12-31 | ₩6.93 Billion | +283.45% |
| 2022-12-31 | ₩-3.78 Billion | -- |
Equity Component Analysis
This analysis shows how different components contribute to S.Biomedics Co. Ltd.'s total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have decreased by 1722408747000.0% over the analyzed period, potentially due to dividend distributions or operating losses.
Current Equity Component Breakdown (December 2024)
| Component | Amount | Percentage |
|---|---|---|
| Common Stock | ₩5.87 Billion | 49.50% |
| Other Components | ₩80.98 Billion | 682.50% |
| Total Equity | ₩11.86 Billion | 100.00% |
S.Biomedics Co. Ltd. Competitors by Market Cap
The table below lists competitors of S.Biomedics Co. Ltd. ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
MEDIPOST Co. Ltd
KQ:078160
|
$201.51 Million |
|
Incar Financial Service Co. Ltd.
KQ:211050
|
$201.56 Million |
|
CITY OFFICE REIT DL -01
F:5QV
|
$201.58 Million |
|
HPGC Renmintongtai Pharmaceutical Corp
SHG:600829
|
$201.76 Million |
|
Infortrend Technology Inc
TW:2495
|
$201.44 Million |
|
Live Oak Acquisition Corp. V Class A Ordinary Shares
NASDAQ:LOKV
|
$201.43 Million |
|
Cubic Sensor and Instrument Co Ltd
SHG:688665
|
$201.40 Million |
|
Zhejiang Qianjiang Biochemical Co Ltd
SHG:600796
|
$201.33 Million |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in S.Biomedics Co. Ltd.'s equity between the two most recent reporting periods.
Equity Growth Insights
- From 2023 to 2024, total equity changed from 6,931,790,800 to 11,864,556,790, a change of 4,932,765,990 (71.2%).
- Net loss of 5,820,879,140 reduced equity.
- Share repurchases of 7,574,431,000 reduced equity.
- Other factors increased equity by 18,328,076,130.
Equity Change Factors (2023 to 2024)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | ₩-5.82 Billion | -49.06% |
| Share Repurchases | ₩7.57 Billion | -63.84% |
| Other Changes | ₩18.33 Billion | +154.48% |
| Total Change | ₩- | 71.16% |
Book Value vs Market Value Analysis
This analysis compares S.Biomedics Co. Ltd.'s book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
- Current price-to-book ratio: 33.41x
- The company is trading at a significant premium to its book value, suggesting the market values its earnings potential, brand, or other intangibles highly.
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 2022-12-31 | ₩-343.74 | ₩33750.00 | x |
| 2023-12-31 | ₩611.43 | ₩33750.00 | x |
| 2024-12-31 | ₩1010.11 | ₩33750.00 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently S.Biomedics Co. Ltd. utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): -49.06%
- The company may be facing challenges in efficiently utilizing shareholder equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: -42.38%
- • Asset Turnover: 0.31x
- • Equity Multiplier: 3.76x
- Recent ROE (-49.06%) is above the historical average (-52.53%), indicating improving capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 2022 | 0.00% | -52.23% | 0.50x | 0.00x | ₩-5.95 Billion |
| 2023 | -108.54% | -57.39% | 0.41x | 4.61x | ₩-8.22 Billion |
| 2024 | -49.06% | -42.38% | 0.31x | 3.76x | ₩-7.01 Billion |
Industry Comparison
This section compares S.Biomedics Co. Ltd.'s net assets metrics with peer companies in the Biotechnology industry.
Industry Context
- Industry: Biotechnology
- Average net assets among peers: $259,224,420,269
- Average return on equity (ROE) among peers: -0.20%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| S.Biomedics Co. Ltd. (304360) | ₩10.46 Billion | 0.00% | 3.24x | $201.45 Million |
| ORIENTBIO Inc. (002630) | $67.35 Billion | -2.60% | 1.21x | $28.37 Million |
| Green Cross (005250) | $282.15 Billion | 18.83% | 0.53x | $229.70 Million |
| Green Cross Holdings Preference Shares (005257) | $1.88 Trillion | -2.88% | 0.99x | $409.02 Million |
| Pharmicell (005690) | $76.66 Billion | 10.78% | 0.43x | $453.92 Million |
| GeneOne Life Science Inc (011000) | $23.71 Billion | -35.27% | 0.34x | $52.94 Million |
| Daesung Microbiological Labs. Co. Ltd (036480) | $19.73 Billion | 2.26% | 0.29x | $14.76 Million |
| Seoulin Bioscience Co.Ltd (038070) | $59.92 Billion | 8.17% | 0.31x | $27.84 Million |
| Hyundai Bioscience Co. Ltd (048410) | $60.94 Billion | 0.00% | 2.69x | $964.67 Million |
| iNtRON Biotechnology Inc (048530) | $49.15 Billion | -1.24% | 0.21x | $83.99 Million |
| Synergy Innovation Co. Ltd (048870) | $71.09 Billion | 0.00% | 0.77x | $77.78 Million |